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Abstract
Invasive fungal infections in children appear to have increased over the past few decades. Especially neonates and children with primary and
secondary immunodeﬁciencies are at risk. Candida and Aspergillus spp. are the most commonly isolated organisms. In addition, Malassezia
may cause systemic infections in newborns and zygomycosis is important because of its rising incidence and high case fatality rate. Timely
diagnosis and initiation of appropriate antifungal therapy is imperative for improving outcomes. However, traditional techniques are time-
consuming and representative sample material, using invasive procedures, may be difﬁcult to obtain in the paediatric setting. This review pro-
vides an overview of the advances in detection and rapid species identiﬁcation, with a focus on issues relevant in these settings. Subsequently,
the current antifungal treatment options for neonates and children are discussed in light of the antifungal spectrum of the available agents
and the speciﬁc pharmacokinetic properties in different age groups. Although a multitude of newer antifungal compounds have become avail-
able within the last decade, further studies are necessary to clearly establish the role for each of these agents among neonates and children.
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Introduction
Invasive fungal infections in children appear to have increased
over the past few decades primarily because there has been
an increase in children with primary or secondary immune
deﬁciencies. The growth in this population that is susceptible
to fungal infections has been mutlifactorial, as a result of: an
increase in neonates surviving preterm delivery, more
intense chemotherapy regimens for the treatment of cancer,
expanded indications for bone marrow and solid organ trans-
plantation, and improved diagnostic and therapeutic modali-
ties for identifying and treating primary immune deﬁciencies
[1–4].
Among immunosuppressed children, the impact of an inva-
sive fungal infection can be devastating, with a high rate of
morbidity and mortality. Timely diagnosis and initiation of
appropriate antifungal therapy is imperative for improving
outcomes. Fortunately, there have been signiﬁcant recent
advances in the ability to more rapidly identify invasive fungal
infections, accompanied by an evolution in the number of
available antifungal agents for treatment. We brieﬂy review
the epidemiology of more commonly identiﬁed invasive fun-
gal infections in children, comment on the important differ-
ences with respect to adults, discuss a number of diagnostic
laboratory techniques, and summarize the currently available
therapeutic options.
Epidemiology
A multitude of fungi have been identiﬁed in the setting of
human infection [5]. A comprehensive discussion of each of
these organisms is beyond the scope of this review. Instead,
the focus will remain on Candida and Aspergillus spp. because
they are the most commonly isolated organisms in paediatric
invasive fungal infections. Malassezia infection and zygomyce-
tes will also be discussed brieﬂy because Malassezia may
cause systemic infections in newborns and zygomycosis
appears to be increasing and has a high case fatality rate.
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Multiple published reports have suggested a steady rise in
paediatric invasive candidiasis ever since the 1970s. In both
children and adults, Candida albicans is the most frequently
isolated species overall, accounting for 50–70% of invasive
candidiasis, depending on the location and the patient popu-
lation studied [6]. Candida parapsilosis is the most common
non-albicans Candida species found in children, accounting
for 15–45% of the infections and, in particular, its incidence
has been increasing among premature neonates. By contrast,
species such as Candida glabrata and Candida krusei, which
are important because of their reduced ﬂuconazole suscepti-
bility, are far less common in children than in adults [6–10].
Aspergillosis is the most common mould infection. Adult
surveillance data have suggested a more than three-fold rise in
aspergillosis in the USA and Europe since 1980 [11,12]. Less
data are available regarding the impact of aspergillosis in chil-
dren. A recent multicentre study suggested that the incidence
of invasive aspergillosis in children, similar to that in adults, is
increasing and results in a greater than 50% case fatality rate.
In both children and adults, Aspergillus fumigatus is the most
frequently isolated species followed by Aspergillus ﬂavus [13].
Chemotherapy for a haematologic malignancy, the presence of
chronic pulmonary disease, solid organ transplantation, or the
use of systemic steroid therapy account for the majority of
adult patients afﬂicted with aspergillosis [14]. In addition to
children with haematological malignancy and solid organ trans-
plantation, children with primary immune deﬁciencies are at
high risk for invasive aspergillosis [13].
Much less is known about the epidemiology of invasive
infections as a result of zygomycetes. Although less common
than aspergillosis, zygomycosis carries a high mortality rate
and, over the past decade, has been increasingly identiﬁed
among immunocompromised adult patients. Among zygomy-
cetes, species of Rhizopus, Mucor and Absidia are most com-
mon. Similar to candidiasis and aspergillosis, the increase in
zygomycosis is considered to be related to a simultaneous
increase in adult haematological malignancies, and bone mar-
row or solid organ transplantation [15–17]. Additionally, the
use of voriconazole for prophylaxis in some adult patients
with malignancy may lead to selection for zygomycetes [18].
Data regarding the epidemiology of non-Aspergillus mould
infections in children are scarce. Extrapolating from the liter-
ature concerning adults, it is likely that such infections are
also increasing in immunocompromised children.
Malassezia is a frequent skin colonizer of neonates. Up to
two-thirds of the hospitalized neonates have been shown to
be skin culture-positive for Malassezia furfur in contrast to
one-third for Candida spp. [19]. The most important risk fac-
tor for systemic Malassezia infection is exposure to lipid-rich
intravenous infusions and most cases are sporadic [20].
However, nosocomial outbreaks with human to human
transmission have been reported and, in the case of the non-
lipophilic species Malassezia pachydermatis, linked to the colo-
nization of healthcare workers’ hands and pet dogs [21].
Mycological Diagnostics
Successful management of invasive fungal infections depends
on timely and correct treatment [22,23]. In contrast to the
scenario for bacterial infections, acquired resistance in fungi
is rare and thus species identiﬁcation is a valuable tool in
guiding the choice of treatment. However, traditional tech-
niques are time-consuming and representative sample mate-
rial, using invasive procedures, may be difﬁcult to obtain in
the paedriatic setting. In the next section, advances in detec-
tion and rapid species identiﬁcation will be reviewed, with a
focus on issues that are relevant in the paediatric setting.
Microscopy
Over the years, the sensitivity, speciﬁcity and speed of
microscopy have been improved with the use of ﬂuorescent
brighteners such as calcoﬂuor white or blankophor [24–26].
The recent development of ﬂuorescent peptide nucleotide
analogue probes speciﬁc for a number of the Candida spp.
has made species identiﬁcation possible directly from a posi-
tive blood culture (Table 1) and the possibility of making an
earlier diagnosis was shown to decrease the use of broad-
spectrum antifungals through early identiﬁcation of C. albicans
cases [27–30]. In the paediatric population, early species
identiﬁcation will reduce the need for broad-spectrum anti-
fungals and, at the same time, minimize the use of echinocan-
dins for C. parapsilosis infections [7,31–34].
Culture
The use of modern automated blood culture systems has
probably led to an increased sensitivity, compared to the
40–60% detection rate of invasive candidiasis reported in the
early 1990s [35]. However, the exact data are limited
because recent autopsy or comparative studies are scarce
[36]. In neonates, a single culture of at least 1 mL of blood
appears to be as sensitive in diagnosing bacterial and fungal
sepsis as two separate peripheral blood cultures [37]. Chro-
mogenic agars allow a presumptive identiﬁcation of several
Candida spp. and facilitate the recognition of yeast isolates in
samples containing several yeasts or yeast and bacteria in
combination [38–41]. Six of the seven Malassezia spp. are
obligate lipophilic species, with the exception being M. pachy-
dermatis. A successful culture of the lipophilic species
requires a lipid-containing medium (Table 1). Conventional
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blood culture medium is not always supportive, but blood
cultures drawn from a central venous catheter used for par-
enteral nutrition or subculture of the broth on lipid contain-
ing agars increase the likelihood of isolation [42]. Finally,
blood cultures are almost always negative in disseminated
aspergillosis.
Rapid species identiﬁcation
Latex agglutination kits are now commercially available and
allow a species identiﬁcation of C. albicans, Candida dubliniensis
and C. krusei within minutes (Table 1) [43–45]. C. glabrata
can be rapidly identiﬁed because of its high amounts of pre-
formed intracellular trehalase enzyme [43,45–48]. Finally,
peptide nucleotide analogue probes and ﬂuorescence micros-
copy can be used [27,29,30].
Antigen detection for yeasts and moulds
Validated antigen detection tests nowadays exist for Aspergil-
lus, Candida and Cryptococcus. In addition, yeast and mould
infections (with the exception of Cryptococcus and zygomyce-
tes) can be detected using a (1,3)-b-D-glucan detection assay
(Table 1). In general, these antigen assays can be used in pae-
diatric patients as in adults; however, speciﬁc issues relative
to their performance in children will be mentioned here.
Paediatric patients with haematological underlying disease
have been included in a number of Aspergillus galactomannan
(GM) studies, but few of these present data by age group
speciﬁcally or include only children [49–53]. In these studies,
however, the sensitivity of the test appears to be in the
same range as in the adult population and is inﬂuenced by
the frequency of sampling, cut-off value and quality of the
clinical Aspergillus classiﬁcation of the patients. Positive results
are available before a positive computed tomography scan or
culture in two-thirds of the patients [53]. In the neonatal
population, false-positive results may occur more frequently,
partly as a result of gut colonization with Biﬁdobacterium spp.
[54–56]. In endemic areas, a positive GM test may also indi-
cate Penicillium marneffei or Histoplasma capsulatum because
these fungi also contain GM in their cell wall [57,58]. Inter-
estingly, it has recently been demonstrated that GM detec-
tion in bronchoalveolar lavage ﬂuids and tissue biopsies may
increase sensitivity [24,59–61].
Mannan antigen as a surrogate marker for the detection of
invasive candidiasis was recently investigated in a neonatal
intensive care setting [62]. With a frequency of conﬁrmed can-
didaemia of 6.5%, the sensitivity and speciﬁcity of the assay
were 94.4% and 94.2%, respectively, and positive and negative
predictive values were 85% and 98%. These results suggest
that the inclusion of regular serological surveillance for man-
nanaemia in some pre-term infants would complement blood
cultures for the early detection of invasive candidiasis. More-
over, the data indicate that the mannan antigen test can be
used without simultaneous detection of anti-mannan antibod-
ies, in contrast to what is recommended in adults [63].
(1,3)-b-D-glucan detection has not been studied speciﬁcally
in the paediatric population and only a few studies have
enrolled children [64–66]. In recent studies in adults, the
performance has been encouraging [67–69], although direct
comparisons with the galactomannan assay for the detection
of aspergillosis do not yield consistent results as to which
test is best [70–73]. Further studies are needed to deter-
mine the performance of this test in the paediatric setting. A
practical drawback is that the test requires incubation and
reading with a kinetic ELISA reader and that the test plates
cannot be divided into separate strips, which leads to a high
cost when running single samples.
D-arabinitol/L- arabinitol ratio
The Candida-speciﬁc metabolite D-arabinitol (DA) has been
used as a surrogate marker of invasive candidiasis by measur-
ing the DA : L-arabinitol (LA) ratio in urine or serum, or the
DA : creatinine ratio in serum. DA analyses have proven
more sensitive than blood cultures in prospective studies of
children and adults with cancer and neutropenia [74,75] and
in premature newborns [76], but less sensitive in non-neu-
tropenic postoperative patients [77]. DA is not produced by
C. krusei and, at least in vitro, not by C. glabrata. However, as
noted earlier, these species are less frequent in children.
PCR
PCR has been the target of major interest because of the
possibility of detecting low amounts of DNA and also non-
viable fungi. There are three challenging problems: (i) the
high degree of homology between human and fungal DNA;
(ii) the effective release of DNA from the fungi despite the
fungal cell wall; and (iii) the risk of contamination of samples,
reagents or equipment, especially when pan-fungal PCRs are
used. As yet, only one commercial PCR blood test has been
marketed that detects the ﬁve most common Candida spp.
and A. fumigatus [78,79]. However, no data are available on
the performance of this test in the paediatric population and
its use is hampered by a very high cost and the fact that one
technician can run only seven samples in 1 day [80]. The
detection of fungaemia using in-house PCR has been evalu-
ated in the neonatal and paediatric intensive care unit (ICU)
setting [81]. Fungaemia with Candida and Malassezia spp. was
diagnosed in nine of nine and one of four cases, respectively,
and, in seven of 13 additional PCR-positive cases, there were
other signs of invasive candidiasis (earlier positive blood cul-
ture, simultaneous candiduria diagnosed using suprapubic
CMI Arendrup et al. Invasive fungal infections 617
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 613–624
puncture, or Candida peritonitis), suggesting that molecular
diagnostics may be a useful adjunct to culture in the high-risk
ICU setting. PCR for the detection of invasive fungal infec-
tions, and aspergillosis in particular, in paediatric patients
with onco-haematological diseases was the object of several
recent studies, with variable results [82–84]. Cesaro et al.
[83] included 536 blood samples from 62 patients, eight of
whom had proven or probable aspergillosis, and found sensi-
tivities of 88–63% (depending on whether one or two posi-
tive test results were required for diagnosis), but high
negative predictive values (95–95%). Bialek, et al. [82]
included 17 neonatal and paediatric children and found a high
rate of false-positive results, leading to a positive predictive
value of 20% when a nested PCR was used. Finally, El-Mahal-
lawy, et al. [84] included 91 patients (15 proven, 13 probable,
14 possible and 49 unlikely IFI cases) and found a sensitivity
of 75% and a negative predictive value of 87% using a pan-
fungal PCR approach. Together, these data show that,
although PCR may have the potential of being an important
part of our diagnostic armamentarium in the future, further
standardization is needed.
Management
Coincident with the improvement in diagnostic techniques
for the identiﬁcation of fungi causing invasive infection, thera-
peutic options have evolved over the past 50 years. Table 2
highlights the appropriate dosing regimens, important phar-
macokinetic properties, and side effects for each of the anti-
fungal agents. Details on the mode of action and
pharmacokinetic/pharmacodynamic data have been presented
elsewhere, although the issues related to the use in children
will be discussed below [8,85–93].
Children, and especially neonates, tolerate conventional
amphotericin B better than adults, and the choice between
this and the three lipid formulations depends on the age of
the patient and on the tolerability of the initial administra-
tion. The lipid formulations are preferable in older children
and for anticipated longer treatment periods. In comparison
with what is observed in adults, the elimination of ﬂuconaz-
ole is slower in neonates (in the ﬁrst 2 weeks of their life),
but more rapid in children. Therefore, speciﬁc dose recom-
mendations by age group are needed. The kinetics of vorico-
nazole metabolism are linear in children and higher doses
are needed to achieve therapeutic levels. Furthermore,
recent evidence suggests that the bioavailability of orally
administered voriconazole is as low as 44% in children
<12 years of age, which is much lower than the estimated
96% in adults [94]. Current data on the use of posaconazole
in children <13 years of age are limited but indicate pharma-
codynamic and toxicity proﬁles similar to those seen in
adults. Because of the fewer side effects and interactions, it
will likely become an important paediatric oral option for
the treatment of various invasive mould infections. Other
second-generation triazoles, such as isavuconazole, ravuco-
nazole and albaconazole, are being evaluated and show
promise in the treatment of invasive fungal infection. There
are no recommendations regarding the use of these newer
triazoles in children [95].
Among the three echinocandins, anidulafungin has not yet
been approved for paediatric use. Considerable data now
exist on the use of caspofungin in children <3 months of age
and its tolerability and efﬁcacy appears similar to that
in adults when dosed by surface area of the child [96–98].
Micafungin has been used with good results in Asia and in
the USA, but it should be noted that in vivo rat studies
showed degenerative and necrotic changes at the hepatocel-
lular level with potential for tumour formation after micafun-
gin exposure. The European Medical Agency has warned
physicians of this potential side effect in humans, speciﬁcally
among children [99,100].
Choosing an antifungal agent
Dedicated guidelines outlining the choices for optimal ther-
apy in the treatment of neonatal or paediatric fungal disease
do not exist. There are guidelines for some invasive fungal
infections in adults that comment on the treatment of these
infections in children [101,102]. On the basis of these adult
guidelines, the epidemiology of invasive fungal infections in
children, and currently available paediatric pharmacokinetic
data, recommendations can be made for optimal therapy in
treating neonatal and paediatric candidiasis, aspergillosis and
zygomycosis.
Treatment of candidiasis
Most available antifungal agents have reasonably broad activ-
ity against C. albicans and the more commonly isolated non-
albicans species. However, there are variations in sensitivity
data across the species. The MICs of ﬂuconazole and also,
but to a lesser extent, of the other azoles are higher for
C. krusei and C. glabrata. The MICs of the echinocandin class
of drugs are elevated for C. parapsilosis, Candida famata and
Candida guilliermondii. Finally, C. krusei is intrinsically resistant
to ﬂucytosine. Acquired resistance has been described in
Candida isolates and is most often associated with a long-
term antifungal treatment. Amphotericin B resistance has
been described in Candida lusitaniae and thus other drug clas-
ses should be used for this species. Acquired azole resistance
has been attributed to mutations in the target gene, to up-
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regulation of the target enzyme and to the expression of
efﬂux pumps. On the other hand, echinocandin resistance in
Candida spp. has been associated with mutations in the gene
encoding the target enzyme glucan synthase and resistance
always appears to concern all three compounds. Fortunately,
sensitivity testing for Candida spp. is now more readily avail-
able and the test results should assist in the ultimate choice
of the antifungal agent [8].
Candida spp. are commonly identiﬁed pathogens in prema-
ture neonates but the lack of available dosing and safety data
limits the therapeutic options in this age group primarily to
amphotericin B and ﬂuconazole. Dosing recommendations
for caspofungin are available for patients as young as
3 months of age. In the setting of suspected neonatal invasive
candidiasis, amphotericin B deoxycholate is the drug of
choice. Neonates tolerate the conventional form of ampho-
tericin B extremely well and there is typically no need to
administer a lipid formulation [8]. Once the isolate is identi-
ﬁed, conversion to ﬂuconazole for the completion of therapy
is reasonable, assuming that the isolate is susceptible [101].
There are a number of treatment options for invasive candi-
diasis in children and adolescents. When instituting empirical
therapy for suspected candidiasis in an immunosuppressed
child, a lipid formulation amphotericin B, an echinocandin or
ﬂuconazole (in the azole-naı¨ve patient not colonized with
C. glabrata or C. krusei) are all reasonable ﬁrst-line therapies. A
fungicidal compound should be considered in severe cases (an
echinocandin or amphotericin B). In the event that aspergillosis
is suspected, voriconazole would be preferred. If the patient
does not have an underlying immunosuppressed condition and
is ﬂuconazole-naı¨ve, or if the identiﬁed Candida spp. is found to
be susceptible to ﬂuconazole, then transition to this agent is
appropriate. In the setting of candidiasis involving the central
nervous system, liposomal amphotericin B should be contin-
ued, with the possible addition of ﬂucytosine for the ﬁrst few
weeks of therapy [101,103].
Treatment of aspergillosis and zygomycosis
Regardless of the age of the patient, surgical excision when
possible should be considered as adjunct therapy to prompt
systemic antifungal therapy. It has been shown, in the largest
paediatric aspergillosis study, that surgical resection is associ-
ated with survival [13]. Recently released guidelines for
adults recommend voriconazole as the agent of choice for
invasive aspergillosis, including central nervous system dis-
ease [102]. This is primarily based on an adult randomized
controlled trial demonstrating that voriconazole was supe-
rior to amphotericin B deoxycholate for the treatment of
invasive aspergillosis [104]. Second-line options for adults
include an amphotericin B formulation, an echinocandin or
posaconazole. A recent adult trial comparing 3 mg/kg/day to
10 mg/kg/day of liposomal amphotericin B showed no
improvement in efﬁcacy, but there was a worse side effect
proﬁle with the higher dosing [105].
Although there have been no paediatric randomized trials
comparing antifungal agents, prospective, open-label studies
have shown similar success with voriconazole in treating pae-
diatric cases of aspergillosis [106]. Therefore, most paediatri-
cians have adopted voriconazole as the drug of choice for
children as young as 2 years of age. First alternatives to
voriconazole for primary or salvage therapy of aspergillosis
should include an amphotericin B formulation or an echino-
candin. In two separate open-label prospective trials, ampho-
tericin B lipid complex and caspofungin were both shown to
be similarily efﬁcacious in the treatment of paediatric invasive
aspergillosis [107,108]. It should also be noted that the spe-
cies Aspergillus terreus has intrinsic resistance to amphotericin
B and thus voriconazole or an echinocandin should be used
in this setting [109].
As noted above, non-Aspergillus moulds, such as the zygo-
mycetes, are much less common but, given their high mortality,
are still important to consider. There have been no random-
ized controlled trials in adults or children; thus, therapeutic
choices are guided by in vitro susceptibility analyses and case
reports. Voriconazole and echinocandins have poor activity,
whereas amphotericin B has reasonable activity against zygo-
mycetes. Therefore, amphotericin B formulations are the
current drug of choice. Posaconazole is currently the only
alternative option for zygomycete infections. However,
appropriate doses of posaconazole are only available for chil-
dren aged 13 years or older [110].
Fortunately, mould infections are uncommon in premature
neonates. When neonates are afﬂicted with Aspergillus or a
zygomycete, it is often a cutaneous infection at the site of
skin trauma from an intravenous catheter or adhesive tape.
These cutaneous infections do carry a risk of dissemination;
thus, the initiation of prompt therapy is imperative. Ampho-
tericin B is the agent of choice for these neonatal mould
infections [111]. Until standard dosing of voriconazole or
echinocandins becomes available, they should only be used
as salvage therapy in neonates.
Antifungal prophylaxis
Because of the increase of invasive fungal disease in prema-
ture neonates and immunosuppressed children, the possibil-
ity of beneﬁts of antifungal prophylaxis is often raised.
For extremely premature neonates, the use of ﬂuconazole
prophylaxis is an attractive option for aiming to reduce inva-
sive candidiasis. A number of randomized trials have been
performed evaluating the beneﬁts of ﬂuconazole for
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4–6 weeks in extremely premature infants. Each of the
randomized controlled trials showed a reduction in the prev-
alence of invasive candidiasis [112–114]. However, they were
all performed in the setting of increased baseline prevalence
rates. The decision to institute a protocol for neonatal anti-
fungal prophylaxis should be based on the prevalance rate of
candidiasis in the neonatal intensive care unit (NICU) [115].
In NICUs with a low prevalence rate, the beneﬁts of prophy-
laxis may not be obvious.
The beneﬁts of prophylaxis for children with haematological
malignancies, bone marrow or solid organ transplantation, or
primary immune deﬁciencies are even less clear. The goal of
prophylaxis in this population would be to reduce invasive
disease from both Candida spp. and moulds. There have been
no signiﬁcant randomized controlled trials evaluating fungal
prophylaxis in any of these settings. Therefore, the routine
administration of antifungal prophylactic agents is not cur-
rently recommended. One exception is the use of itraconaz-
ole prophylaxis routinely in children diagnosed with chronic
granulomatous disease. There are limited data supporting
this practice and, certainly, itraconazole is not completely
protective in all children with chronic granulomatous disease
[116]. Randomized trials are necessary to guide appropriate
prophylaxis recommendations among these at-risk, paediatric
populations.
Combination therapy
The availability of antifungal agents with varied mechanisms
of action has prompted suggestions for combination antifun-
gal therapy. A number of in vitro, in vivo and human studies
have been performed, evaluating various antifungal agent
combinations. Thus far, there is no conclusive evidence doc-
umenting the deﬁnitive beneﬁts of any combination for anti-
fungal therapy. However, the combination of amphotericin B
and ﬂucytosine is recommended for Candida infections
involving the central nervous system [101].
Therapeutic drug monitoring
Monitoring in general is indicated in two scenarios: (i) drug
exposure may be inadequate as a result of pharmacokinetic
variability and may contribute to treatment failure or (ii)
drug exposures may exceed those anticipated and may result
in toxicity [117]. Krishna, et al. [118] studied outcome in
relation to posaconazole levels in children and demonstrated
that drug levels vary mainly because of inconsistent absorp-
tion and that drug levels correlate with outcome. Voriconaz-
ole shows linear kinetics of the metabolism in children [119],
although variable drug levels are observed because of genetic
differences in the rate of metabolism and concomitant medi-
cation [120]. The bioavailability of itraconazole depends on
the route of administration (oral vs. parenteral), on formula-
tion (liquid vs. capsules) and on inter-individual variation
[121]. Levels can be monitored using bioassays or chemical
methods. Recommended trough levels for prophylaxis are
>0.5 mg/L for all three azoles. For treatment, these levels
are: voriconazole, 1–6 mg/L; itraconazole, >1 mg/L; and posa-
conazole, 0.5–1.5 mg/L [117].
Conclusions
The number of premature neonates and immunocompro-
mised children susceptible to invasive fungal infections has
been increasing. To successfully manage these challenging
infections, paediatricians and subspecialists need to remain
aware of the optimal diagnostic and therapeutic options.
When diagnosing an invasive fungal infection, clinicians should
work closely with the local mycologist to effectively utilize
both traditional and novel diagnostic tools. Similarly, when
initiating antifungal therapy, physicians need to be up-to-date
concerning the speciﬁc pharmacokinetic properties of anti-
fungal agents for treatment of children. A multitude of newer
antifungal medications have become available in the last dec-
ade, but further studies are necessary to clearly establish the
role for each of these agents among neonates and children.
Lastly, the availability of various classes of antifungal agents
raises the possibility of improved outcomes with combination
therapy. However, until further data become available, any
beneﬁts of combination therapy will remain theoretical.
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